A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.
M. J. Birrer
No relevant relationships to disclose
P. Konstantinopoulos
No relevant relationships to disclose
R. T. Penson
Research Funding - Massachusetts General Hospital
M. Roche
No relevant relationships to disclose
A. Ambrosio
No relevant relationships to disclose
T. E. Stallings
Employment or Leadership Position - BiPar Sciences
U. Matulonis
No relevant relationships to disclose
C. R. Bradley
Employment or Leadership Position - BiPar Sciences